Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE ...
2 days ago · Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals PRESS RELEASE GlobeNewswire Jan. 8, 2025, 12:30 PM
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva ...
1 day ago · On Wednesday, Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd (NYSE:TEVA). This Agreement resolves the patent litigation ...
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With …
1 day ago · Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United States till Feb. 25, 2035.
Catalyst settles with Teva, staving off Firdapse generic until 2035
1 day ago · Teva’s generic version of the med, amifampridine, has not yet been approved by the FDA. Catalyst’s share price jumped more than 16% before market close Wednesday on news of the settlement.
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE ...
2 days ago · CORAL GABLES, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") CPRX, a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A. (“SERB”) have entered into a ...
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE ...
2 days ago · The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen.
Catalyst Pharma and Teva Settle Firdapse Patent Litigation
2 days ago · Teva gets a license to market generic FIRDAPSE in the US starting February 2035 as part of a settlement with Catalyst Pharmaceuticals. This resolves the patent litigation brought by Catalyst and its licensor SERB in response to Teva’s ANDA seeking approval to market a generic version of FIRDAPSE (amifampridine) 10 mg tablets prior to …
FDA Approves Dose Expansion of Catalyst's Amifampridine for …
Jun 3, 2024 · The FDA has approved a supplemental new drug application (sNDA) for a higher maximum daily dose of Catalyst Pharmaceuticals’ potassium channel blocker amifampridine (Firdapse) for the treatment of adults and pediatric patients with Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune neuromuscular disorder characterized primarily by muscl...
News & Events | FIRDAPSE® (amifampridine) - HCP
On May 30, 2024, Catalyst Pharmaceuticals, Inc. received approval by the U.S. Food and Drug Administration (FDA) increasing the indicated maximum daily dose of FIRDAPSE (amifampridine) for adults from 80 mg to 100 mg for the treatment of …
Catalyst Pharmaceuticals Announces FDA Acceptance of the
Oct 13, 2023 · Catalyst's flagship U.S. commercial product is FIRDAPSE ® (amifampridine) Tablets 10 mg, approved for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS") for adults and for children ages...
- Some results have been removed